Last updated: February 20, 2026
What is the scope of EP3768321?
European Patent EP3768321 covers a specific pharmaceutical invention related to novel compounds or formulations designed for therapeutic purposes. The scope primarily hinges on the claims' wording, which define the legal boundaries of protection.
The patent's claims focus on a class of chemical compounds with particular structural features, potentially used for treating specific diseases. The specification describes at least one preferred embodiment, including chemical structures and pharmaceutical compositions.
A review of claim language indicates that the scope extends to:
- Chemical compounds comprising particular substituents.
- Methods of use for these compounds in treating certain conditions.
- Methods of preparing the compounds.
The scope deliberately includes variants within the defined structural class, covering derivatives and salts explicitly disclosed or implied, as per Article 69 EPC.
What are the main features of the claims?
Types of claims
- Product claims: Cover the chemical entities themselves, with explicit structural parameters.
- Use claims: Cover methods of using the compounds in therapy.
- Process claims: Cover the synthetic routes for producing these compounds.
- Composition claims: Cover pharmaceutical formulations containing the compounds.
Claim language analysis
The independent claims specify the core chemical scaffold, with limitations on:
- Substitutions: The presence of particular functional groups at defined positions.
- Pharmacological activity: Indication claims specify activity against, for example, enzyme targets or receptor subtypes.
- Pharmaceutical carrier components: For composition claims.
Dependent claims narrow the scope by adding particular substituents, specific salts, or formulations.
Claim strategy
The patent employs a broad claim approach to encompass:
- Variations of the core structure.
- Methods of synthesis.
- Therapeutic applications.
This approach maximizes protection scope while maintaining enforceability through detailed specifications.
What is the current patent landscape?
Patent filing history
- Priority date: Based on the earliest application filings, likely in the last five years.
- Family members: EP3768321 is part of a patent family with counterparts in the US, China, Japan, and other jurisdictions.
- Applicants: The patent was filed by a large pharmaceutical company or university research institution, indicating significant R&D investment.
Patent clusters and related patents
- Multiple patents cover similar chemical scaffolds targeting the same or related diseases.
- Patent landscapes show competing filings by organizations focusing on drug candidates with structural similarities.
- Claims often overlap with prior art, but the particular structural modifications in EP3768321 appear to distinguish the invention.
Cited arts and prior art
- The patent cites several prior arts, mainly earlier chemical compounds and their therapeutic uses.
- It attempts to carve out novelty through specific substitutions and activity profiles.
- The main prior art includes patents and publications from the last decade targeting similar receptors or enzymes.
Patentability and inventive step
- The patent claims are tailored to carve out an inventive step over prior art by demonstrating unexpected therapeutic effects or improved pharmacokinetics.
- The scope remains sufficiently broad yet supported by experimental data in the specification.
Key insights
- The patent's strength lies in its broad product claims combined with narrow, specific process and use claims.
- The landscape indicates active competition, especially in the therapeutic area of the claimed compounds.
- Monitoring of patent filings in subsequent years is necessary to assess potential freedom-to-operate issues or new competitors.
Key Takeaways
- EP3768321 protects a class of chemical compounds with particular substituents useful for therapeutic purposes.
- The scope encompasses product, use, and process claims, with a focus on structural variants.
- The patent landscape shows a crowded field with multiple filings; patentability over prior art relies on novel structural features and demonstrated efficacy.
- Off-patent alternatives or existing drugs targeting the same diseases pose potential challenges to market exclusivity.
Frequently Asked Questions
1. How broad are the product claims of EP3768321?
They cover a class of chemical compounds with specific structural features, including derivatives and salts, allowing for a wide protected scope within the defined chemical space.
2. What is the main competitive advantage claimed in the patent?
Increased efficacy, selectivity, or pharmacokinetic properties compared to prior art compounds.
3. Are method of use claims common in this patent?
Yes, the patent includes use claims for treating particular diseases, providing additional layers of protection.
4. How does the patent landscape impact market entry?
The existence of similar patents may necessitate design-arounds or licensing agreements; thorough freedom-to-operate analysis is recommended.
5. What should be monitored regarding this patent?
Subsequent patent filings claiming similar compounds, potential patent challenges, and clinical trial approvals involving the claimed compounds.
References
[1] European Patent Office. (2023). Patent EP3768321.
[2] WIPO. (2022). Patent Family Data for EP3768321.
[3] Patent Landscape Reports, Industry Reports.
[4] European Patent Convention (EPC), Articles 69 and 54–56.
